Stay updated on Sabatolimab in HMA for Higher Risk MDS Clinical Trial

Sign up to get notified when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-01T13:14:07.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces changes to NIH websites and explains that some content may use “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    0.5%
    Check dated 2026-10-25T13:15:39.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The website footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T13:31:47.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now identifies site revision v3.7.1 instead of v3.7.0.
    Difference
    0.1%
    Check dated 2026-10-11T13:35:17.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page's Revision tag was updated from v3.6.6 to v3.7.0, reflecting a new version of the Study Record History page. This indicates an under-the-hood update to the page template rather than a change to the study information.
    Difference
    0.1%
    Check dated 2026-09-20T10:38:15.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision metadata in the history has been updated from v3.6.5 to v3.6.6, signaling a minor version bump in the site's revision tracking.
    Difference
    0.1%
    Check dated 2026-08-29T23:56:59.000Z thumbnail image

Stay in the know with updates to Sabatolimab in HMA for Higher Risk MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.